Emerging Drugs and Targets for Alzheimer's Disease: Complete Set

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the elderly. The Bloomberg School of Public Health recently estimated that over 26 million people were living with AD in 2006 and that the number will grow to 106 million by 2050. Interventions that delay onset by just one year could reduce the 2050 figure by 12 million. This demonstrates the importance and social need of finding an effective therapeutic intervention. Both volumes gather together some of the most promising examples of drugs now in pharmaceutical development, and new targets currently going through a validation process. It describes the discovery and development history of the disease modifying therapeutics most likely to reach the Alzheimer's market in the next few years. It will be of interest to both those working in the pharmaceutical industry and in academia from graduate level onwards.
Contents

VOLUME 1
Beta-Amyloid as target
Chapter 1: The amyloid hypothesis of AD and prospects for therapeutics
Chapter 2: Targeting Alzheimer's ?-Secretase: Genetic and Chemical Modulation
Chapter 3: Cholesterol and AD: the molecules, the targets
Chapter 4: The Bimodal Features of Butyrylcholinesterase in Cholinergic Neurotransmission and Amyloid Suppression
Chapter 5: Scyllo-inositol, a potential therapy for Alzheimer's disease
Chapter 6: Immunotherapeutic strategies toward treatment of AD
Tau protein as target
Chapter 7: Alzheimer Neurofibrillary Degeneration: Pivotal Role and Therapeutic Targets
Chapter 8: Multiple roles of glycogen synthase kinase-3 in AD
Chapter 9: Tau protein kinases inhibitors: from the bench to the clinical trials
Chapter 10: Activating PP2A as a therapeutic intervention strategy in AD
Chapter 11: Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies
Glucose Metabolism as target
Chapter 12: Insulin Insulin Resistance and neurodegeneration: Type 2 versus type 3 diabetes mellitus
Chapter 13: Insulin-like Growth Factor I as a disease-modifying therapy in Alzheimer's disease
Chapter 14: Ketone bodies as a therapeutic for Alzheimer's disease
VOLUME 2 Neuronal Plasticity as target
Chapter 15: Regeneration of Degenerated Brain: A Promising Therapeutic Target
Chapter 16: Promoting synaptic resilience in AD patients through PDE inhibition
Chapter 17: A new generation of non invasive NGF-based therapies for Alzheimer's disease
Chapter 18: Possible clinical applications of stem cell strategies in AD therapies
Neuronal protection as target
Chapter 19: Targeting Oxidative Mechanisms in Alzheimer Disease
Chapter 20: Davunetide (NAP) Pharmacology: Neuroprotection and tau
Chapter 21: Targeting NF- B inflammatory and pro-survival signaling in AD
Chapter 22: PPAR in Alzheimer's disease
Miscellaneous targets and strategies
Chapter 23: Serotonin 5-HT4 receptors as pharmacological targets for the treatment of Alzheimer's disease
Chapter 24: Liver X Receptors as potential therapeutic target for AD
Chapter 25: Discovery of memoquin, a multi-target-directed ligand for the treatment of Alzheimer's disease Chapter 26. RNA interference of genes related to AD B. Nawrot Chapter 27. Medicinal plants, phytochemicals and Alzheimer's Disease D. Kennedy

OUR VISITORS OPINIONS

There are no opinions yet. Please be the first to add one.

write a review